Tebentafusp: Side Effects, Uses & Monitoring
Facts extracted from current FDA product labeling for Tebentafusp. Educational only — not medical advice.
Labeled uses
KIMMTRAK is indicated for the treatment of HLA-A*02:01-positive adult patients with unresectable or metastatic uveal melanoma.
Source: FDA labeling via NIH DailyMed (set 24a49f57…). Not affiliated with FDA or NIH.
Medical disclaimer: Always consult a qualified healthcare professional about any medication.